The initial event in the life cycle of a virus is its interaction with speci®c receptors present on the surface of a cell. Understanding these interactions is important to our understanding of viral tropism and tissue speci®c pathology associated with viral disease. The human polyomavirus, JCV, is the etiological agent of the fatal central nervous system (CNS) demyelinating disease, progressive multifocal leukoencephalopathy (PML). PML is the direct result of JCV infection of oligodendrocytes, the myelin producing cell in the CNS. In vivo, JCV can be detected in oligodendrocytes, astrocytes, lymphoid tissue, and peripheral blood of PML patients. In vitro, JCV infects human glial cells, tonsilar stromal cells, and, to a limited extent, human B lymphocytes. The initial step in infection of cells by JCV is at the level of attachment and entry. A speci®c cell surface receptor for JCV on human glial cells has not been identi®ed. To begin to understand the nature of JCV receptors on human glial cells, large quantities of a previously characterized hybrid JC virus (Mad-1/ SVED) were puri®ed. A direct virus binding assay demonstrated that these highly puri®ed and labeled JCV virions bound to a ®nite number of cellular receptors on human glial cells. A competitive virus binding assay demonstrated that an excess of unlabeled JCV competed with labeled JCV more ef®ciently than did an excess of puri®ed SV40. Furthermore, anti-class I antibodies which inhibited infection of glial cells by SV40 had no signi®cant effect on infection by JCV. These results imply that JCV does not share receptor speci®city with the related polyomavirus, SV40.
Introduction
Seroepidemiological studies indicate that greater than 70% of the human population worldwide is infected with the human polyomavirus, JCV (Major et al., 1992; Walker and Frisque, 1986) . The mode of virus transmission is unknown, and no clinical illness has been associated with primary infection. Like other polyomaviruses, infection with JCV is associated with the establishment of lifelong latent or persistent infections (Norkin, 1982; Walker and Frisque, 1986) . Reactivation of JCV in chronically immunosuppressed patients leads to virus dissemination to the central nervous system and subsequent infection of glial cells (Lipton, 1991; Major et al., 1992; Telenti et al., 1992; Tornatore et al., 1994) . Alternatively, JCV genomes may establish latency in the CNS and become reactivated during immunosuppression (Elsner and Dorries, 1992; Mori et al., 1991; Quinlivan et al., 1992; Vago et al., 1996; White et al., 1992) . The primary targets of virus infection in the CNS are oligodendrocytes and astrocytes. The fatal demyelinating disease, progressive multifocal leukoencephalopathy (PML), results from lytic destruction of oligodendrocytes by JCV. JCV has also been associated with several neural and non-neural tumors, including medulloblastoma, neuroblastoma, glioblastoma, pineocytoma, and B cell lymphoma (Major et al., 1992; Tornatore et al., 1994) . Recently, the JCV oncoprotein, large T antigen was detected in an oligoastrocytoma in an immunocompetent patient (Rencic et al., 1996) .
The initial step in the establishment of virus infection is the interaction between the virus and receptors present on the surface of cells and tissues. In general, viruses that have a very narrow host range and tissue tropism, such as JCV, are often shown to interact with high af®nity to a limited number of speci®c receptors present on susceptible cells (Haun et al., 1993; Marsh and Helenius, 1989) . In some instances virus tropism is strictly determined by the presence of speci®c receptors that mediate binding and entry (Bai et al., 1993; Dalgleish et al., 1984; Haywood, 1994; Klatzman et al., 1984; Mendelsohn et al., 1989; Philipson et al., 1968; Racaniello, 1990; Tomassini et al., 1989; Weiss, 1993; Weiss and Tailor, 1995; Wickham et al., 1993) . In other instances, however, successful entry into a cell is necessary but not suf®cient for virus growth (Atwood, 1991; Bass and Greenberg, 1992; Mei and Wadell, 1995; Rossman, 1994) . In these cases, additional permissive factors that interact with viral regulatory elements are required.
SV40 is the only member of the polyomavirus family for which a speci®c cell surface protein has been identi®ed as a virus receptor (Atwood and Norkin, 1989; Breau et al., 1992) . In a series of studies it was found that major histocompatibility complex (MHC) encoded class I proteins were a major component of the SV40 receptor on rhesus monkey kidney cells (Atwood and Norkin, 1989; Breau et al., 1992) . It has recently been shown that entry of infectious SV40 into cells is mediated by caveolae and that MHC class I proteins play an essential role in targeting of SV40 to these structures (Anderson et al., 1996; Stang et al., 1997) . The distribution and levels of MHC class I protein expression on numerous human cell types do not always correlate with susceptibility to infection by SV40 (Atwood, 1991; Basak et al., 1992) . This indicates that additional factors contribute to SV40 tropism. These additional factors may be speci®c transcription factors, the presence of a coreceptor, or both. It is clear from several studies that the mouse polyomavirus (PyV) and the lymphotropic papovirus (LPV) do not share receptor speci®city with SV40 (Clayson and Compans, 1989; Haun et al., 1993; Sanjuan et al., 1992) . Nlinked glycoproteins containing terminal a2-3 linked sialic acids are a critical component of the cell surface receptor for the mouse polyomavirus (Cahan and Paulson, 1980; Cahan et al., 1983; Fried et al., 1981; Hermann et al., 1997) . Recent studies have suggested a possible role for a2-6 linked sialic acids as well (Chen and Benjamin, 1997) . The cell surface receptor for the lymphotropic papovirus, LPV, involves O-linked glycoproteins with terminal a2-6 linked sialic acids (Huan et al., 1993; Keppler et al., 1994 Keppler et al., , 1995 .
Very little is known about the early steps of JCV binding to and entry into glial cells. Studies addressing this critical point in the virus life cycle have been hampered by the relatively poor growth of JCV, even in human glial cells. We have overcome this problem by using a previously characterized hybrid JC virus (Mad-1/SVED). The non-coding regulatory region of this virus is a hybrid between SV40 and the Mad-1 strain of JCV (Vacante et al., 1989) . The coding sequences, including the late capsid coding region, are entirely from the Mad-1 strain of JCV (Vacante et al., 1989) . When propagated in the human SV40 transformed glial cell line, SVG, Mad-1/SVED yielded 30-fold higher levels of virus than the Mad-4 strain of JCV. We have taken advantage of this and successfully puri®ed and labeled JCV virions derived from the Mad-1/SVED infected glial cells. The binding of labeled JCV virions to SVG cells was saturable, indicating that JCV binds to a limited number of cell surface receptors. In a competitive virus binding assay, an excess of unlabeled JCV virions competed with labeled JCV virions more ef®ciently than did an excess of puri®ed SV40 virions. Furthermore, pretreatment of glial cells with anti-MHC class I antibody inhibted infection by SV40 but not by JCV. These results imply that JCV does not share receptor speci®city with the related polyomavirus, SV40.
Results
High level production of Mad-1/SVED in SVG cells We compared the growth of the Mad-1/SVED hybrid virus with a Mad-4 isolate by infecting SVG cells with identical amounts of either virus. At weekly intervals the cultures were assessed for cytopathic effect and the supernatants collected and assayed for virus by hemagglutination assay (HA). appreciable cytopathology until 3 weeks postinfection (Figure 1 ). At 4 weeks post-infection when the Mad-4 infected cultures showed extensive cytopathology the cells were harvested for virus stock (Figure 1 ). Weekly virus yields from the Mad-1/SVED infected cells were always signi®cantly higher than from the Mad-4 infected cells (Table 1 ). The total virus yield from the Mad-1/SVED infected cultures was 32 times greater than the Mad-4 infected cultures (Table 1) .
Determination of the purity of cesium chloride FITC-labeled JCV Polyacrylamide gel electrophoresis and Western blotting were used to assess the purity of the FITClabeled virus preparation. Five micrograms of FITClabeled virus was resolved on a reducing and denaturing 12% polyacrylamide gel. A single FITC-labeled band migrating at approximately 39 kD was apparent upon exposure of the gel to UV light. This suggests that the FITC label is exclusively associated with the major JCV capsid protein, VP1 ( Figure 2 , lanes 7 and 8). The 39 kD band and some additional bands were seen after the gel was stained with Coomassie blue (Figure 2 , lanes 5 and 6). A duplicate gel was blotted to a Nytran membrane and individual lanes on the blot probed with either anti-BSA or anti-SV40 antisera. The anti-SV40 antisera has been previously shown to crossreact with JCV VP1. The blots were then incubated with a secondary goat anti-rabbit antibody conjugated to horseradish peroxidase. Speci®c bands were detected by a chemiluminescence assay. Puri®ed BSA and cesium chloride puri®ed SV40 were used as controls for the anti-BSA antibody and the anti-SV40 antibody respectively. The anti-SV40 antibody con®rmed that the 39 kD band seen in the gel exposed to UV light and in the Coomassie blue stained gel was indeed JCV VP1 (Figure 2 lane 4). We were able to detect BSA contamination in our cesium chloride puri®ed FITC-labeled JCV preparation which is consistent with the recent published work of others ( Competition between JCV and SV40 for binding to SVG cells To determine whether JCV and SV40 compete for binding to SVG cells both viruses were puri®ed by cesium chloride density gradient centrifugation. The amount of protein in the puri®ed virus samples was determined as described in Materials and methods. For the competition experiments SVG cells were incubated in buffer alone or in buffer containing a 100-fold or a tenfold excess of either unlabeled JCV, unlabeled SV40, or unlabeled BSA. FITC-labeled JCV was then added and the amount of labeled virus bound determined by¯ow cytometry. The binding of FITC-labeled JCV to SVG cells in the presence of a 100-fold and a tenfold excess of unlabeled JCV was reduced by 38% and 20% respectively (Figure 4a and c). In contrast, the binding of FITC-labeled JCV to SVG cells in the presence of a 100-fold and a tenfold excess of unlabeled SV40 was reduced by 12.8% and 3% respectively (Figure 4b and c) . A 100-fold and a tenfold excess of BSA inhibited the binding of labeled JCV by 5.2% and 6% respectively (Figure 4c ).
Effect of anti-class I antibody on infection of SVG cells by JCV and SV40
MHC class I proteins are known to be a component of the SV40 receptor on monkey kidney cells (Atwood and Norkin, 1989; Breau et al., 1992) . The direct competition experiment above does not rule out the possibility that JCV also associates with MHC antigens on SVG cells. MHC class I proteins are not constitutively expressed on glial cells in vivo, however, under a variety of pathological conditions, MHC antigen expression can be induced on these cells. One report demonstrated the presence of MHC class I proteins on glial cells in active PML lesions (Achim and Wiley, 1992) . This raises the possibility that JCV, like SV40, could potentially associate with MHC class I antigens on the cell surface. To address this possibility we ®rst determined whether our glial cell line expressed MHC class I antigens. SVG cells were incubated with a dilution series of the monoclonal anti-MHC class I antibody, BB7.7. The cells were then washed 36 and incubated with a secondary goat anti-mouse FITC labeled antibody. Constitutive expression of class I antigens was detected on these cells ( Figure  5 ). We next asked whether this anti-class I antibody could inhibit infection of SVG cells by JCV. As a control we tested the ability of the antibody to inhibit infection of SVG cells by SV40. Pretreatment of the cells with anti-class I antibody inhibited infection by SV40 by 57% (Figure 6 , compare the stippled bar to cross hatched bar). In contrast the same pretreatment had no signi®cant effect on infection by JCV (Figure 6 , compare the stippled bar to the cross hatched bar).
Discussion
The results presented here represent the ®rst attempt to study the interaction of JCV with cellular receptors on human glial cells. This critical event in the life cycle of JCV has not previously been studied due to the relatively poor growth of JCV, even in human glial cells. We have taken advantage of a previously characterized JC virus that contains a hybrid JCV/SV40 regulatory region. The hybrid virus induced signi®cant cytopathology in the SVG human glial cell line and large numbers of progeny virions were produced. The receptor binding characteristics of the hybrid virus are those of the Mad-1 strain of JCV. The increased growth of the hybrid is due to the presence of a hybrid SV40/JCV regulatory region (Vacante et al., 1989) . These attributes make this hybrid virus ideal for studying JCV receptor interactions. To study the binding of JCV to glial cells we chose to label the virus with FITC. This labeling method was chosen so that virus binding to discreet populations of cells could be detected by¯ow cytometry. In our ®rst virus binding experiment we observed that 1024 hemagglutination units of FITC-labeled JCV completely saturated cell surface receptors on 2610 5 SVG cells. It has been estimated that one hemagglutination unit contains 1610 7 physical particles (Crawford, 1969) . Using this estimate we can calculate the number of JCV particles in 1024 hemagglutination units at 1610 10 . This indicates that an SVG cell contains at least 50 000 JCV receptors. Similar estimates have arrived at 90 000 SV40 receptors on monkey kidney cells, 25 000 polyomavirus receptors on mouse ®broblasts, and 800 ± 1800 LPV receptors on human B cells (Clayson and Compans, 1988; Haun et al., 1993; Herrmann et al., 1995 Herrmann et al., , 1997 .
To determine the speci®city of JCV binding to glial cells we measured binding in the presence and absence of an excess of unlabeled JCV, unlabeled SV40, or unlabeled BSA. We found that labeled JCV was competitively inhibited by an excess of unlabeled JCV but not by an excess of SV40 or BSA. The relatively low amount of inhibition even at a 100-fold excess of unlabeled JCV suggests that a signi®cant portion of JCV binding to glial cells is non-speci®c. Experiments are underway that will directly measure the kinetics of JCV binding to glial cells.
As SV40 infection of monkey kidney cells is known to be inhibited by antibodies directed at MHC class I proteins we tested whether these antibodies would inhibit infection of glial cells by JCV. We ®rst con®rmed that MHC encoded class I proteins were expressed on SVG cells. We next tested the ability of anti-MHC antibody to inhibit infection of the SVG cells by both SV40 and JCV. We found that the anti-class I antibody only inhibited infection by SV40. This result indicates that infection of SVG cells by JCV is not dependent on an interaction with class I proteins. We have previously demonstrated that anti-class I antibodies have no effect on infection of primary cultures of human glial cells by the Mad-1 strain of JC virus (our unpublished observations). These results, when taken together, imply that JCV and SV40 do not share receptor speci®city on human glial cells. The nature of speci®c JCV receptors on glial cells and their role in determining viral tropism is currently under investigation.
Materials and methods

Cells, virus and antibody
The human glial cell line, SVG, was derived by transformation of human fetal glial cells by an origin defective SV40 mutant and has been previously described (Major et al., 1985) . SVG cells were maintained in a humidi®ed 378C CO 2 incubator in Eagles' Minimum Essential Media (E-MEM; Mediatech Inc., Herndon, VA) supplemented with 10% heat inactivated fetal bovine serum (Mediatech Inc., Herndon, VA). Hybridoma cells were grown in suspension in RPMI-1640 Hybrimax 1 media (Sigma, St. Louis, MO) supplemented with 10% heat inactivated fetal bovine serum (Mediatech Inc., Herndon, VA). The Mad-4 strain of JCV was isolated from cultures of persistently infected Owl monkey glioblastoma cells and has been previously described (Major et al., 1987) . The hybrid Mad-1/SVED virus was constructed by insertion of the regulatory region of SV40 into the regulatory region of the Mad-1 strain of JCV (Mad-1/ SVE) (Vacante et al., 1989) . Propagation of Mad-1/ SVE in human glial cells led to deletions and alterations exclusively in the regulatory region. The rearranged regulatory region contains the origin of replication, the TATA box and 78 base pairs of the ®rst 98 base pair repeat from JCV and one complete 72 base pair repeat from SV40. Most of the 72 base pair repeats and the 21 base pair repeats from SV40 were deleted. The virus is termed Mad-1/SVED to indicate this fact. A comparison of the restriction patterns of Mad-1/SVED DNA with the prototype Mad-1 DNA were identical except for the regulatory region changes just discussed (Vacante et al., 1989) . No additional alterations were apparent following subsequent passage of Mad-1/ SVED in human fetal glial cells (Vacante et al., 1989) . The host range of the hybrid has been extended to include human embryonic kidney, and Rhesus monkey fetal glial cells (Vacante et al., 1989) . SV40, strain 776, was propagated in the African green monkey kidney cell line, CV1. CV1 cells were obtained from American Type Culture Collection (ATCC, Rockville, MD) and were maintained identically to SVG cells. The PAB597 hybridoma produces a monoclonal antibody against the SV40 major capsid protein, VP1 and was generously provided by Ed Harlow. This antibody has previously been shown to cross-react with JCV VP1 (Atwood et al., 1995) . The BB7.7 hybridoma produces a monoclonal antibody directed at major histocompatibility encoded class I proteins and was obtained from ATCC.
Virus puri®cation and labeling
For puri®cation of Mad-1/SVED virions, 1610 8 SVG cells were incubated with 3200 hemagglutination units (HAU) of virus at 378C for 1 h. Supernatants and dead cells were collected weekly from the infected cultures and stored at 7208C. At 3 week post-infection when the cells showed extensive cytopathic effect they were removed from the dishes by scraping. The dead cells and culture¯uid from the previous 2 weeks were combined with this material and pelleted by centrifugation at 2000 r.p.m. for 30 min. The resulting cell pellet was suspended in 30 ml of the supernatant and subjected to 3 freeze-thaw cycles. Deoxycholic acid was then added to 0.25% and the suspension was incubated at 378C for 1 h. Cell debris was removed by centrifugation at 5000 r.p.m. and the supernatants were layered on a cushion of cesium chloride (CsCl) (1.34 g/ml). Virus was banded by centrifugation for 24 h at 35 000 r.p.m. in a SW55Ti rotor. The virus band was removed and dialyzed extensively against phosphate buffered saline (PBS) (137 mM NaCl, 2.682 mM KCl, 8.1 mM Na 2 HPO 4 , 1.47 mM KH 2 PO 4 , pH 7.2). Puri®ed virus was stored in 100 ml aliquots at 7808C. Virus titers were determined by hemagglutination assay (HA) on human type O erythrocytes. SV40 was puri®ed in an identical manner from infected CV1 cells. SV40 titers were determined by plaque assay. A portion of the gradient puri®ed JCV was dialyzed against uorescin isothiocyante (FITC) labeling buffer (0.05 M Boric Acid, 0.2 M NaCl, pH 9.2). The concentration of protein in the puri®ed virus preparation was determined by the method of Bradford (1976) . Puri®ed virus (2.0 mg) was then incubated for 8 h at room temperature with 50 ml of a 5.0 mg/ml solution of FITC (Sigma, St. Louis, MO) dissolved in DMSO (Sigma, St. Louis, MO) (Harlow and Lane, 1988) . The FITC-labeled virus was puri®ed a second time by centrifugation over a cushion of cesium chloride. The FITC-labeled virus band was visualized with a hand-held UV light, removed, and dialyzed extensively against PBS (pH 7.2). The ratio of FITC to protein was determined by spectrophotometry.
Western blotting and polyacrylamide gel electrophoresis Equivalent amounts (5.0 mg) of puri®ed bovine serum albumin (BSA) (Fraction V, Fisher Biotech, Spring®eld, NJ), gradient puri®ed SV40, or gradient puri®ed and FITC-labeled JCV were diluted in Laemmli sample buffer (0.5 M Tris-HCl (pH 6.8) 10% (v/v glycerol, 10% (w/v) SDS, 0.1% (w/v) Bromphenol blue containing b-mercaptoethanol. The samples were heated at 958C for 5 min and resolved on a 12% Tris-HCl polyacrylamide gel (Bio-Rad Laboratories, Hercules, CA) in Tris-glycine buffer containing SDS. The gel was exposed and photographed on a UV lightbox to detect FITClabeled bands. Total proteins on the gel were detected by staining with coomassie blue. A duplicate gel was electroblotted to Nytran membranes (Schleicher and Schuell, Keene, NH). The ef®ciency of protein transfer was determined by staining the blot with 0.1% (w/v) Ponceau S. Individual lanes were cut into strips and the strips blocked overnight in 16TBST (137 mM NaCl, 25 mM Tris, 2.7 mM KCl, 0.05% Tween 20) containing 5% non-fat dry mlik. The strips were incubated overnight with rabbit anti-BSA antibody (Sigma, St Louis, MO), or rabbit anti-SV40 antibody (gift from L Norkin) diluted 1 : 1000 in blocking buffer. The strips were washed 16 in RIPA buffer (150 mM NaCl, 1.0% (v/v) NP-40, 0.05% (w/v) deoxycholate, 0.1% (w/v) SDS, 50 mM Tris (pH 8.0) and 26 in TBST. The strips were incubated for 4 h with a goat anti-rabbit HRP conjugated antibody (1 : 1000 dilution). The strips were washed 16 in RIPA buffer and 26 in TBST. The strips were developed by incubation in equal parts of chemiluminescent reagents (ECL-kit, Amersham, Arlington Heights, III) and bands were detected by after exposure on Kodak XAR ®lm (Rochester, NY). TM¯o w cytometer. For antibody binding, SVG cells were removed from culture dishes by a brief incubation in a Trypsin/EDTA solution (0.05% trypsin, 0.53 mM EDTA-4Na) (Mediatech Inc., Herndon, VA). The cells were then washed 36 in HBSS 2% sera and suspended at a concentration of 1610 6 /ml in HBSS 2% sera. 1610 6 cells were then incubated with a dilution series of hybridoma tissue culture supernatant containing the anti-class I antibody BB7.7 for 30 min on ice. Control cells were incubated with media alone. The cells were then washed 36 in HBSS 2% sera and incubated with a 1 : 50 dilution of FITC labeled goat anti-mouse IgG (Jackson Immunoresearch Laboratories Inc., West Grove, PA) for an additional 30 min on ice. The cells were then washed 26 in HBSS 2%, 16 in PBS, and ®xed in PBS containing 1% paraformaldehyde. The cells were analyzed as described above. For the competition assay, 1610 5 SVG cells were preincubated for 30 min at 48C with or without 0.3 mg of unlabeled JCV, unlabeled SV40, or unlabeled BSA. FITC-labeled JCV virions (0.03 mg or 0.003 mg) were then added to the cells and incubated for an additional 30 min on ice. The cells were washed 26 in HBSS 2% sera, 16 in PBS, and ®xed in PBS containing 1% paraformaldehyde. The cells were analyzed as described above.
Antibody and virus binding assays
Infectivity assay SVG cells growing on duplicate coverslips were either mock infected or infected with increasing dilutions of SV40 or JCV. At days 1 ± 6 post-infection the cells were washed 36 in PBS and ®xed in ice cold acetone. The percentage of infected cells were determined by indirect immuno¯uorescent assay of V antigen expressing cells. This was done by incubating the ®xed cells with a 1 : 10 dilution of the anti-V antigen monoclonal antibody PAB 597 for 30 min at 378C. The cells were then washed 36 in PBS and incubated with a 1 : 50 dilution of goat antimouse FITC labeled antibody for 30 min at 378C. The cells were washed 16 with PBS, 16 with PBS containing 0.02% Evan's blue (counterstain), and 26 with PBS. V antigen positive cells were visualized on a Zeiss epi¯uorescent microscope and scored by counting. On average 300 ®elds containing between 70 and 100 cells per ®eld were counted. V antigen expression peaked at 2 days postinfection with SV40 and at 3 days post-infection with JCV. For the infection blocking experiment 2610 5 SVG cells growing on duplicate coverslips were pretreated with 100 ml of media or 100 ml of undiluted anti-MHC class I antibody (BB7.7-hybridoma supernatant) for 30 min on ice. The cells were then infected with SV40 (MOI=1) or with 10 HAU of JCV for an additional 30 min on ice. The cells were washed three times in PBS and incubated at 378C in media. At various times post-infection the cells were washed 36 in PBS and ®xed for 10 min in ice cold acetone. The percentage of infected cells was determined by indirect immuno¯uorescent assay of V antigen expressing cells as described above.
